GTG settles yet another DNA patent suit
18 September, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has announced the latest settlement in its US patent enforcement efforts and finalised the terms for a proposed US$5m issue of convertible notes.
New genes for an old breed
12 September, 2013A new breeding technique and an old wheat cultivar are combining to produce quality wheat faster.
Unravelling the essentials of the Y chromosome
06 September, 2013 by Susan WilliamsonAn enzyme that 'unravels' DNA plays a key role in male development of the embryo and may provide greater insight into intersex conditions.
GTG cleared to sell BREVAGen in NY
03 September, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has received the approval required to launch breast cancer test BREVAGen in NY, meaning the company can now provide the product in all 50 US states.
Breeding sorghum to feed the world
30 August, 2013Whole genome resequencing reveals sorghum contains much more genetic variation than previously realised.
GTG secures extra $800k through capital raising
28 August, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has arranged to place an extra $800k in shares to sophisticated investors, and to increase the underwriting for its planned SPP to $1.8m.
Mimicking a cure
14 August, 2013 by Fiona WylieA collaboration of Melbourne scientists who describe themselves as a “happy confluence” is shedding much-needed light on how the body controls nervous system myelination, and how their tiny peptide ‘mimic’ could help patients with neurodegenerative disease.
DNA - a silent witness
07 August, 2013 by Graeme O’NeillForensic science is about to be transformed with the use of new technology to predict a person’s physical appearance - a molecular photofit derived from DNA found at a crime scene.
Supercomputer switched on
01 August, 2013Ranked as one of the largest supercomputers in the world, Australia’s fastest supercomputer has been turned on.
Big genome
17 July, 2013 by Graeme O'NeillDebate continues about the claim that proteins interact with 80% of the human genome and whether this much regulation is required for a functional human being.
GTG posts record BREVAGen sales growth
02 July, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) said its BREVAGen genetic testing business has been growing faster every quarter since its expansion to the US in mid-2011.
Genetic variations found in people with allergies
01 July, 2013Genetic differences between people who develop allergies and those who don’t have been identified.
US patent verdict “troubling”: BIO
19 June, 2013 by Dylan Bushell-EmblingThe head of US biotech industry group BIO has argued that the recent Supreme Court verdict on DNA patents could cause problems but he welcomed the ruling that the restrictions do not apply to composite DNA (cDNA) that is distinguishable from naturally occurring sequences.
GTG expects no impact from US gene verdict
18 June, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) believes a US Supreme Court patent ruling should have no material impact on its commercial operations.
Bioengineering a new kidney
18 June, 2013Queensland researchers have reprogrammed adult kidney cells to act as stem cells to repair damaged kidneys.
